top of page
News, Events and Updates
Search
Feb 4, 2022
Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 AVATAR Phase 3 Trial
Feb 3, 2022
Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, 2/9/2022
Feb 1, 2022
ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints
Jan 10, 2022
Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71
Jan 6, 2022
Anavex Life Sciences Promotes Dr. Kaufmann to CSO and Appoints Dr. Hammond as CMO
Jan 5, 2022
Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
Dec 14, 2021
Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Nov 29, 2021
Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
Nov 24, 2021
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results
Nov 17, 2021
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wed., November 24, 2021
Nov 10, 2021
Building Global Momentum for Interventions in Alzheimer's Disease - a Lausanne VIII Workshop Panel
8
9
10
11
12
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
